The United Kingdom and the United States have signed a landmark commercial pact that will maintain zero import taxes on British medicine products going into the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has pledged to boost expenditure on pharmaceuticals through the National Health Service (NHS). This commitment secures that tariffs on these vital exports will be held at zero for a timeframe of the next three years.
This development follows previous statements to significantly raise tariffs on patented drug imports, with potential rates discussed reaching 100%.
"This deal between the Britain reinforces the global environment for cutting-edge drugs and introduces much-needed equity to American-British pharmaceutical trade," a statement noted.
Commercial Importance
Medicines are one of the the United Kingdom's biggest export categories to the US, which is easily the biggest market for large companies like GSK and AstraZeneca.
Statistics show that in the 12 months to the end of September, the UK sold drugs totaling billions to the US. This amount made up 17.4% of all goods exports in that timeframe.
"This deal protects work, boosts funding and facilitates the UK to become a global hub for biotech and pharma," a minister remarked.
Key NHS Changes
The agreement involves several specific commitments from the British government:
- Price Threshold Increase: The UK will lift the cost ceiling at which it judges new treatments to be too expensive by a quarter.
- Increased NHS Spending: There is a target to increase total NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Refund Ceiling: The percentage drug companies must pay back to the NHS to prevent overspending will be limited at 15%. Last year, repayments topped 20%.
Industry Background
This agreement follows a protracted dispute between the drug companies and the UK government over drug pricing and regulatory access.
This friction were intensified by arguments that US customers were charged significantly more for the equivalent treatments than consumers in the Britain and the EU.
In recent months, several significant drug company projects in the UK have been delayed or abandoned, while major investments have been pledged toward American operations.
One official stated that the NHS must invest a greater share on drugs, noting that its budget allocation on drugs had declined as a proportion of its total funding over the previous ten-year period.
